Introduction
============

COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) was developed to identify people with severe, high-risk undiagnosed COPD, defined as a forced expiratory volume in 1 second (FEV~1~) \<60% predicted or exacerbation risk, in primary care settings.[@b1-copd-13-1901],[@b2-copd-13-1901] This case-finding method uses five simple patient-completed questions and the selective use of peak expiratory flow (PEF) to uncover individuals most likely to benefit from diagnosis and treatment.[@b1-copd-13-1901]--[@b8-copd-13-1901] The intent is to be as efficient as possible, using PEF selectively based on questionnaire score and reserving spirometry referrals to the subset of patients whose results warrant further diagnostic evaluation.[@b1-copd-13-1901],[@b3-copd-13-1901],[@b4-copd-13-1901]

Although this case-finding method was developed to identify undiagnosed patients with an FEV~1~% predicted \<60% or at risk of exacerbation, uncovering symptomatic patients with FEV~1~% predicted \>60% who might also benefit from treatment could be advantageous. This study explored the extent to which CAPTURE identifies these patients.

In its initial testing, CAPTURE was able to differentiate cases of COPD (FEV~1~% predicted \<60% or exacerbation risk) from controls without COPD with a sensitivity (SN) of 89.7% and specificity (SP) of 93.1% (n=273). When subjects with milder COPD (FEV~1~% predicted ≥60% and no/low exacerbation risk) were included in the control group, testing the ability of CAPTURE to differentiate the more severe, high-risk patients from all others, SN was 89.7% and SP was 78.1% (n=346).[@b1-copd-13-1901] The change in SP indicated that CAPTURE was classifying some patients with milder airflow obstruction as cases, a finding interpreted as error because the intent was to find the more severe, high-risk patients.[@b1-copd-13-1901] Upon further reflection, we questioned whether these "misclassified" cases may represent an additional group of patients who might also benefit from diagnosis and treatment. Although screening of asymptomatic individuals for undiagnosed COPD is not recommended,[@b9-copd-13-1901] identifying symptomatic patients with mild-to-moderate airflow limitation could be advantageous, with treated individuals potentially realizing symptomatic, activity tolerance, and health-status benefits.[@b10-copd-13-1901]--[@b14-copd-13-1901]

Methods
=======

Design
------

This was a secondary analysis of data from the prospective, cross-sectional, multisite, case--control study used to develop CAPTURE.[@b1-copd-13-1901],[@b15-copd-13-1901] Specific methods and procedures for the larger study are presented elsewhere.[@b1-copd-13-1901] The study was approved by a central institutional review board (IRB) (Schulman Associates) and IRBs at each study site (Columbia University, National Jewish Health, Olmsted Medical Center, University of Kentucky, University of Michigan, and University of Nebraska Medical Center). Each patient provided written informed consent before initiating study procedures. Briefly, for questionnaire development, a pool of 44 candidate questions and criterion measures were completed by patients identified as cases (n=186; FEV~1~ \<60% or ≥1 exacerbation the previous 12 months) or controls (n=160; including patients with COPD and FEV~1~ \<60% predicted and no exacerbations the prior 12 months \[n=73\] and those without COPD \[n=87\]).[@b1-copd-13-1901] COPD was defined by physician diagnosis with prescribed pharmacologic maintenance therapy and FEV~1~/FVC \<0.70. COPD patients with an FEV~1~% predicted of 60%--80% were included in the control group to optimize the selection of items most sensitive to more severe, high-risk COPD during random forests analyses. The precision of the questionnaire alone, PEF alone, and CAPTURE (Questionnaire+PEF) for differentiating cases (n=186) from non-COPD controls (n=87) was also tested.[@b1-copd-13-1901]

To address the purpose of the current study, analyses were performed on data from the original control group (n=160), with cases defined by a diagnosis of COPD, FEV~1~ ≥60% predicted, and no exacerbation the prior 12 months (n=73) and those with no COPD serving as controls (n=87). The entire dataset (n=346) was used to evaluate CAPTURE across the full range of COPD (n=259), with patients without COPD (n=87) serving as controls.

Measures
--------

### The CAPTURE Questionnaire

The CAPTURE Questionnaire ([Figure 1](#f1-copd-13-1901){ref-type="fig"}) comprises five questions assessing the presence/absence of symptoms (breathing problems and tiring easily), risk exposures, and recent history of acute respiratory illnesses. Responses are summed to yield a score ranging from 0 (no to all 5 questions) to 6 (yes to all questions and \>2 respiratory events during the past year). Scores ≥2 indicate that further diagnostic assessment for COPD is warranted. In its initial testing, scores ≥2 showed an SN of 95.7% and an SP of 44.4% for differentiating COPD cases (FEV~1~% predicted \<60% or exacerbation risk) from controls (mild/moderate no risk COPD or no COPD) and an SN of 95.7% and an SP of 67.8% for differentiating cases from those without COPD.[@b1-copd-13-1901]

### PEF

PEF is used to increase the precision of case identification. In the development/validation study, research staff supervised PEF administration (Vitalograph^®^ AsmaPlan^®^ mechanical PEF meter; Vitalograph Ltd, Buckingham, UK) during the clinic visit; each subject performed three maneuvers with the highest value (L/min) used for analyses. Sex-specific thresholds were identified to facilitate rapid interpretation in clinical practice prior to referral for diagnostic spirometry: males \<350 L per minute (L/min) and females \<250 L/min.[@b1-copd-13-1901]

### CAPTURE (Questionnaire+PEF)

Questionnaire scores are used to select the best subset of patients for PEF testing. Those scoring 0 or 1 on the questionnaire are unlikely to have COPD and can proceed with the remainder of their clinic visit. Those scoring 5 or 6 (yes to all items and ≥1 respiratory events the past year) may have undiagnosed disease and can be referred directly to spirometry. Patients scoring 2--4 are clinically equivocal, with PEF values relative to thresholds used to determine next steps (spirometry and no spirometry). In the development study, this two-step process, using the 350/250 L/min thresholds, improved SN and SP over the questionnaire alone for differentiating cases and controls (89.7% and 78.1%) and cases and no-COPD controls (89.7% and 93.1%), with the added advantage of eliminating the need for PEF assessments in all patients.[@b1-copd-13-1901]

### Modified British Medical Research Council dyspnea scale (mMRC) and COPD Assessment Test (CAT™)

The mMRC[@b16-copd-13-1901],[@b17-copd-13-1901] and CAT™[@b18-copd-13-1901],[@b19-copd-13-1901] were used to assess patient-reported dyspnea and COPD-related health status, respectively. The mMRC is a 5-point (0--4) scale with higher ratings reflecting more severe breathlessness. CAT scores range from 0 to 40 with higher scores indicating poorer COPD health status. Patient-level scores \<10 are interpreted as low-impact COPD, with continued health maintenance interventions advised, including smoking cessation, vaccination, and exercise. Scores 10--20 are considered moderate-impact COPD with potential for improvement with treatment, for example, maintenance therapies, reduction in aggravating factors, exacerbation prevention, and/or rehabilitation.[@b20-copd-13-1901] mMRC \>2 and CAT scores \>10 are used to categorize patients as "more symptomatic" under the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.[@b21-copd-13-1901]

### Spirometry

Pre-bronchodilator spirometry (FEV~1~, FEV~1~% predicted, and FEV~1~/forced vital capacity \[FVC\]) was performed if spirometry results from the past 5 years were not available. FEV~1~/FVC \<0.70 and FEV~1~ \<80% predicted were considered diagnostic of COPD. All COPD cases met COPD Foundation Guide spirometry grade 1 requirements (FEV~1~ ≥60%; \<80% predicted).[@b7-copd-13-1901]

Analyses
--------

Group differences in sample characteristics were tested using parametric (normally distributed continuous variables) and nonparametric (categorical and non-normal continuous variables) statistics. PEF values were also compared using analysis of variance, with factors for group, sex, smoking, age, and group-by-sex interaction.

The precision of the questionnaire, PEF (350/250), and CAPTURE (Questionnaire+PEF \[350/250\]) for differentiating patients with and without COPD in this sample was estimated using SN, SP, overall misclassification error estimates, receiver operator characteristic curves, and area under the curve.

The SN, SP, and error for PEF alone were examined in 25 mL increments stratified by sex to determine if higher thresholds more accurately differentiated these cases of COPD from those without COPD, with consideration given to threshold values that would be easy to recall and apply in clinical settings. The best thresholds were then tested with the questionnaire to determine if new thresholds for males and females would enhance the precision of CAPTURE in this population.

The extent to which CAPTURE was identifying COPD patients with dyspnea (mMRC levels \>2) and/or poor health status (CAT scores \>10) was tested using Chi-square (*χ*^2^) or Fisher's exact (cell n \<5) statistics and performed using the 350/250 and the higher PEF thresholds.

Finally, SN, SP, and error for differentiating the full range of COPD (n=259) from no COPD (n=87) were assessed for the questionnaire alone, PEF alone, and CAPTURE using the 350/250 and higher PEF thresholds.

Results
=======

Sample
------

Demographic and clinical characteristics of the analytical sample are shown in [Tables 1](#t1-copd-13-1901){ref-type="table"} and [2](#t2-copd-13-1901){ref-type="table"}. Subjects without COPD were younger and more likely to be female, employed, and have a higher educational level than the COPD group.

Of the 73 patients with milder COPD, 23 (31.5%) were GOLD airflow limitation category 1 (mild) and 50 (68.5%) were GOLD 2 (moderate).[@b21-copd-13-1901] COPD patients had significantly poorer lung function, higher mMRC and CAT scores, and were more likely to have a smoking history and one or more comorbid conditions than those with no COPD. PEF rates were significantly lower in the COPD group, tested alone and controlling for age (*p*\<0.001), sex (*p*\<0.0001), and smoking status (*p*\<0.01) (LS means \[95% CI\]: COPD \[n=73\]: 324.3 \[301.6; 346.9\]; no COPD \[n=87\]: 403.1 \[381.2, 425.1\]; F=27.78; *p*\<0.001).

CAPTURE performance
-------------------

Performance properties of the questionnaire, PEF, and questionnaire+PEF for these milder COPD cases versus no COPD are shown in [Table 3A](#t3-copd-13-1901){ref-type="table"} and [Figure 2A](#f2-copd-13-1901){ref-type="fig"}. To assist with interpretation, results for the more severe high-risk COPD cases (FEV~1~ \<60% or risk of exacerbation) versus no COPD controls from the original development study[@b1-copd-13-1901] are provided in [Table 3B](#t3-copd-13-1901){ref-type="table"} and [Figure 2B](#f2-copd-13-1901){ref-type="fig"}. Results for all COPD versus no COPD are shown in [Table 3C](#t3-copd-13-1901){ref-type="table"} and [Figure 2C](#f2-copd-13-1901){ref-type="fig"}. SN analyses for smoking status are included in [Tables S1](#SD1-copd-13-1901){ref-type="supplementary-material"}[](#SD2-copd-13-1901){ref-type="supplementary-material"}--[S3](#SD3-copd-13-1901){ref-type="supplementary-material"}, with results suggesting that this was not a confounding factor.

### Questionnaire alone

Most COPD patients (61/73; 83.6%) scored ≥2 on the questionnaire, the threshold for further evaluation of COPD. The questionnaire was less sensitive differentiating milder COPD from no COPD (83.6%, [Table 3A](#t3-copd-13-1901){ref-type="table"}), relative to its use detecting more severe cases of COPD (95.7%, [Table 3B](#t3-copd-13-1901){ref-type="table"}).

### PEF alone

PEF (350/250 threshold) was less sensitive differentiating milder COPD patients from those without COPD (38.4%, [Table 3A](#t3-copd-13-1901){ref-type="table"}) relative to its performance with more severe cases of COPD (88.0%, [Table 3B](#t3-copd-13-1901){ref-type="table"}). Precision estimates for PEF at 25 L/min increments are shown in [Table S4A and B](#SD4-copd-13-1901){ref-type="supplementary-material"}. Increasing the threshold by 100 L/min (to 450/350 for males/females) improved the SN of PEF from 38.4% to 83.6%, with some sacrifice in SP, from 90.8% to 66.7% ([Table 3A](#t3-copd-13-1901){ref-type="table"}).

### CAPTURE (Questionnaire+PEF)

As one might expect given its purpose and development methods, CAPTURE (PEF 350/250) had substantially lower SN for detecting patients with milder airflow obstruction (39.7%, [Table 3A](#t3-copd-13-1901){ref-type="table"}) compared to the detection of patients with more severe, high-risk COPD (89.7%, [Table 3B](#t3-copd-13-1901){ref-type="table"}). Using CAPTURE (PEF 450/350) improved the SN from 39.7% to 71.2%, with some sacrifice in SP, from 93.1% to 83.9% ([Table 3A](#t3-copd-13-1901){ref-type="table"}).

### Dyspnea and health status

Most of the milder COPD patients scoring ≥2 on the questionnaire reported either dyspnea (mMRC ≥2; n=50/60; 83.3%) or health status impairment (CAT ≥10/60; n=54/60; 88.5%). For patients with questionnaire scores \<2, most (9/12; 75%) had an mMRC \<2 (mMRC missing for one subject) or CAT \<10 (9/12, 75%).

COPD patients whose CAPTURE (PEF 350/250) indicated the need for further diagnostic evaluation (n=29) were more likely to report dyspnea (mMRC scores ≥2, *p*\<0.05) than those who did not (n=44). There was no difference in health status (CAT ≥10) between the two groups ([Table S5](#SD5-copd-13-1901){ref-type="supplementary-material"}).

Using the higher PEF threshold, COPD patients whose CAPTURE (PEF 450/350) suggested further evaluation (n=52) were more likely to be symptomatic (mMRC ≥2 and CAT ≥10, *p*\<0.01) than patients whose scores suggested that no further assessment was warranted (n=21) ([Table S3](#SD3-copd-13-1901){ref-type="supplementary-material"}).

Using CAPTURE to detect a full range of COPD, mild to severe
------------------------------------------------------------

As expected, using CAPTURE (PEF 350/250) to differentiate all patients with COPD from those without COPD alters the precision of the case-finding approach relative to its original purpose, reducing SN (89.7%--75.5%) and increasing error (9.2%--20.1%). Increasing the PEF threshold improves SN from 75.5% to 88.0% and reduces error (20.1%--13.0%), with some sacrifice in SP (declines from 93.1% to 83.9%).

Discussion
==========

CAPTURE was designed to help primary care health professionals efficiently identify severe, high-risk undiagnosed cases of COPD in greatest need of diagnosis and treatment. Many patients with FEV~1~ \>60% are symptomatic, however, and may also benefit from treatment.[@b10-copd-13-1901],[@b11-copd-13-1901],[@b13-copd-13-1901],[@b14-copd-13-1901] The results of the analyses presented here suggest that CAPTURE can identify these milder patients with reasonable SN and SP when PEF thresholds of 450/350 are used. Although more patients would be referred for diagnostic spirometric testing, including those without COPD, a substantial portion of those ultimately diagnosed with COPD are likely to have dyspnea or health status impairment that may be ameliorated with treatment.

Given the performance properties of PEF in the current analyses and previous study, one might be tempted to use PEF thresholds alone to identify patients in need of spirometry. However, organizing PEF supplies and performing three coached maneuvers with all patients in primary care settings, in addition to other clinic visit assessments, could be challenging. Furthermore, results of PEF provide preliminary information on airflow obstruction only, with no insight into exposure, symptoms, or exacerbation risk prior to referral for diagnostic testing. CAPTURE was designed to balance efficiency and precision, with the carefully designed questionnaire used as an initial screen and PEF administered to a subset of patients to yield fewer false positives and reduce screening costs. The PEF thresholds enable efficient interpretation, with empirically tested quick-recall values (male/female, moderate to severe: 350/250; mild to moderate: 450/350), although clinicians can also use the observed value and clinical judgment to determine the need for further assessment and testing.

Given the relatively high CAT scores in patients with questionnaire scores ≥2, one might also ask if the CAT could be used for case finding. The CAT was developed to facilitate communication between COPD patients and clinicians,[@b18-copd-13-1901] covering eight common manifestations of COPD and scores used to guide treatment. It was neither intended for use in patients without COPD nor as a screening tool. Following diagnosis, the CAT can be used to guide treatment and monitor outcomes.[@b22-copd-13-1901]

Several limitations of this study should be noted. First, this was an analysis of data from a subset of subjects participating in the CAPTURE development study, rather than a large prospective, population-based case-finding study. Results should be considered exploratory. Second, the COPD and no COPD groups differed on several sample characteristics. Some of these differences typify COPD and were expected; however, differences in demographics (particularly age, sex, and education) and smoking history could have affected the findings. Although there is no reason to believe that demographic differences altered patient responses to study measures, this must be recognized as a limitation with further study warranted. SN analyses in former smokers suggested that results were robust to smoking history. Third, spirometry values were measured without bronchodilator administration with the standard FEV~1~/FVC diagnostic threshold of \<0.70. Although other diagnostic indicators were also used for group assignment (medical diagnosis and treatment), the 0.70 threshold can result in an overestimation of older subjects with airflow limitation. Once again, further research is needed. Fourth, although CAPTURE has been tested and performs well identifying more severe, high-risk cases of COPD in Spanish-speaking patients,[@b2-copd-13-1901] sample size precluded testing its performance in milder symptomatic COPD. Finally, CAPTURE is a tool to identify patients requiring further evaluation for COPD; it was not intended to diagnose or evaluate treatment and may detect problems other than COPD that warrant evaluation. It was also not intended for use as an outcome measure, with the CAT best suited to that purpose following diagnosis.

Conclusion
==========

Results of these analyses together with those from the original validation study suggest that CAPTURE can be used to identify symptomatic patients likely to have airflow limitation and in need of further clinical evaluation for possible COPD. Based on the patient's score on this questionnaire, clinicians can apply the 350/250 or 450/350 PEF thresholds as they determine the need for diagnostic spirometry. Further testing in a large prospective study of this case-finding approach and its effect on diagnosis, treatment, and patient-centered outcomes are warranted.

Supplementary materials
=======================

Sensitivity analyses: former smokers
------------------------------------

Given the difference in smoking status between the two groups, SN analyses were performed, testing the performance of the questionnaire, PEF, and CAPTURE (Questionnaire+PEF \[350/250 and 450/350\]) for differentiating COPD and no COPD in former smokers only (n=56). Demographic and clinical characteristics of former smokers by group are shown in [Tables S1](#SD1-copd-13-1901){ref-type="supplementary-material"} and [S2](#SD2-copd-13-1901){ref-type="supplementary-material"}. Results are presented in [Table S3](#SD3-copd-13-1901){ref-type="supplementary-material"}. SN, SP, and error were similar to values found in the entire sample ([Table 3](#t3-copd-13-1901){ref-type="table"}), suggesting that smoking history was not a confounding factor.

Peak expiratory flow (PEF)
--------------------------

Each subject performed three PEF maneuvers using a Vitalograph^®^ AsmaPlan^®^ mechanical PEF meter (Vitalograph Ltd, UK), with the highest value (L/min) used for analysis. Performance properties of PEF at varied thresholds in this sample stratified by sex are shown in [Table S4](#SD4-copd-13-1901){ref-type="supplementary-material"}.

Clinical characteristics of patients whose COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) suggests that further diagnostic evaluation is advised
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CAPTURE was developed to identify patients in need of diagnostic evaluation for undiagnosed COPD and a forced expiratory volume in 1 second (FEV~1~) \<60% or exacerbation risk. This study assessed the sensitivity (SN), specificity (SP), and error of this case-finding method for identifying patients with an FEV~1~ ≥60% predicted.

To assess whether the evaluation process was identifying symptomatic patients, dyspnea (modified Medical Research Council \[mMRC\] \>2), or health status impairment (COPD Assessment Test \[CAT™\] \>10) was examined. [Table S5](#SD5-copd-13-1901){ref-type="supplementary-material"} shows the results of these analyses for the 350/250 and 450/350 PEF thresholds. In both cases, most of the patients who would be referred for further diagnostic evaluation reported impaired health status and a substantial portion reported dyspnea. Although more patients are referred for further testing when the higher PEF threshold (450/350) is used, those referred are more likely to report impaired health status or high levels of dyspnea compared to those whose scores suggested that no further testing was warranted. These results suggest that CAPTURE (PEF 450/350) may be useful for identifying cases of COPD with an FEV~1~ \>60% predicted, many of whom meet GOLD guidelines for "more symptomatic" disease.

###### 

Demographic characteristics of former smokers (N=76) by group

  Characteristic                                                          Former smokers (N=76)   *p*-value     
  ----------------------------------------------------------------------- ----------------------- ------------- --------
  Age (years)                                                                                                   
   Mean (SD)                                                              67.4 (7.9)              62.0 (11.1)   0.0284
   Range                                                                  51--85                  40--88        
  Sex, n (%) male                                                         24 (50)                 10 (36)       0.2270
  Ethnic background, n (%)                                                                                      
   Not Hispanic or Latino                                                 46 (98)                 28 (100)      1.000
  Racial background, n (%)[d](#tfn28-copd-13-1901){ref-type="table-fn"}                                         
   White                                                                  44 (92)                 25 (89)       
   Non-white                                                              4 (8)                   3 (11)        0.7039
  Employment, n (%)                                                                                             
   Employed (full- or part-time)                                          10 (21)                 10 (21)       0.0052
   Not employed/others[e](#tfn29-copd-13-1901){ref-type="table-fn"}       38 (79)                 38 (79)       
  Education status, n (%)                                                                                       
   High school or less                                                    22 (46)                 22 (46)       0.0934
   Some college, vocational training                                      9 (19)                  9 (19)        
   College degree or more                                                 17 (35)                 17 (35)       

**Notes:**

English-speaking with informed consent and spirometry;

COPD, FEV~1~ 60%--80% predicted and no history of exacerbations \>12 months;

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70;

Subject self-identified; non-white: American Indian or Alaskan Native (1, 1), Asian (0, 1), Black or African American (1, 2), others (1, 0).

Others: homemaker, unemployed, and not specified.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Clinical characteristics of former smokers (N=76) by group

  Characteristic                             COPD[b](#tfn32-copd-13-1901){ref-type="table-fn"} (n=48)   No COPD[c](#tfn33-copd-13-1901){ref-type="table-fn"} (n=28)   *p*-value
  ------------------------------------------ ---------------------------------------------------------- ------------------------------------------------------------- -----------
  Spirometry, mean (SD)                                                                                                                                               
   FEV~1~, median                            1.9                                                        2.4                                                           0.0023
   Mean (SD)                                 2.0 (0.6)                                                  2.5 (0.7)                                                     
   FEV~1~% predicted, median                 68.0                                                       85.0                                                          0.0020
   Mean (SD)                                 73.5 (13.2)                                                85.0 (17.3)                                                   
   FEV~1~/FVC                                0.60 (0.06)                                                0.78 (0.06)                                                   \<0.0001
  Peak flow (PEF)                            320.9 (114.7)                                              396.3 (85.0)                                                  0.0035
  mMRC (0--4 scale)                                                                                                                                                   
   Median                                    1                                                          0                                                             \<0.0001
   Mode (n, %)                               1 (24, 51)                                                 0 (25, 89)                                                    
   mMRC \>2, n (%)                           12 (26)                                                    1 (4)                                                         0.0243
  CAT™                                                                                                                                                                
   Median                                    15.0                                                       5.0                                                           \<0.0001
   Mean (SD)                                 14.5 (6.6)                                                 5.5 (4.7)                                                     
   CAT \>10, n (%)                           38 (79)                                                    5 (18)                                                        \<0.0001
  mMRC \>2 and CAT \>10, n (%)               12 (26)                                                    1 (4)                                                         0.0243
  mMRC \>2 or CAT \>10, n (%)                38 (79)                                                    5 (18)                                                        \<0.0001
  Comorbid conditions (any), n (%), yes      48 (100)                                                   25 (89)                                                       0.0466
  Self-report activity on most days, n (%)                                                                                                                            
   Sit, lie down, walk around home           26 (54)                                                    10 (36)                                                       0.1202
   Very active or exercise                   22 (46)                                                    18 (64)                                                       

**Notes:**

English-speaking subjects with informed consent and spirometry;

COPD, FEV~1~ 60%--80% predicted and no history of exacerbations \>12 months;

no known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.

**Abbreviations:** CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified Medical Research Council dyspnea scale.

###### 

Performance of the questionnaire, PEF, and CAPTURE[c](#tfn37-copd-13-1901){ref-type="table-fn"} for differentiating COPD[a](#tfn35-copd-13-1901){ref-type="table-fn"} (n=48) from No COPD[b](#tfn36-copd-13-1901){ref-type="table-fn"} (n=28) in former smokers (N=76)

  Property          Questionnaire   PEF[c](#tfn37-copd-13-1901){ref-type="table-fn"}   CAPTURE[c](#tfn37-copd-13-1901){ref-type="table-fn"} (Questionnaire +PEF)          
  ----------------- --------------- -------------------------------------------------- --------------------------------------------------------------------------- ------ ------
  Sensitivity (%)   87.5            33.3                                               81.3                                                                        39.6   70.8
  Specificity (%)   67.9            92.9                                               57.1                                                                        96.4   85.7
  Error (%)         19.7            44.7                                               27.6                                                                        39.5   23.7

**Notes:**

COPD, FEV~1~ 60%--80% predicted, and no history of exacerbations \>12 months;

no known diagnosis or treatment for COPD and FEV~1~/FVC ≥ 0.70.

PEF rate (L/min), thresholds: males/females.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.

###### 

Performance properties of PEF thresholds for differentiating milder cases of COPD[a](#tfn39-copd-13-1901){ref-type="table-fn"} from patients without COPD[b](#tfn40-copd-13-1901){ref-type="table-fn"} by sex

  Males (n=66)                                                
  ----------------- ------ ------ ------ ------ ------ ------ ------
  Sensitivity (%)   37.5   52.5   65.0   80.0   80.0   82.5   85.0
  Specificity (%)   88.5   88.5   80.8   69.2   65.4   53.8   50.0
  Error (%)         42.4   33.3   28.8   24.2   25.8   28.8   28.8

  Females (n=94)                                       
  ----------------- ------ ------ ------ ------ ------ ------
  Sensitivity (%)   39.4   66.7   69.7   75.8   87.9   93.9
  Specificity (%)   91.8   86.9   85.2   80.3   67.2   42.6
  Error (%)         26.6   20.2   20.2   21.3   25.5   39.4

**Notes:**

COPD, FEV~1~ 60%--80% predicted and no history of exacerbations \>12 months.

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.

PEF rate, L/min.

Selected threshold.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.

###### 

Prevalence of dyspnea and health status by CAPTURE™ Response[a](#tfn44-copd-13-1901){ref-type="table-fn"} in patients with COPD[b](#tfn45-copd-13-1901){ref-type="table-fn"} (N=73)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                 CAPTURE (PEF 350/250)[c](#tfn46-copd-13-1901){ref-type="table-fn"}\   CAPTURE (PEF 450/350)[d](#tfn47-copd-13-1901){ref-type="table-fn"}\                                
                                 Diagnostic testing recommended                                        Diagnostic testing recommended                                                                     
  ------------------------------ --------------------------------------------------------------------- --------------------------------------------------------------------- -------- --------- --------- --------
  mMRC \>2, n (%)                12 (43)                                                               8 (18)                                                                0.0227   19 (37)   1 (5)     0.0042

  CAT™ \>10, n (%)               26 (90)                                                               31 (70)                                                               0.0817   45 (86)   12 (57)   0.0060

  mMRC \>2 and CAT \>10, n (%)   12 (43)                                                               8 (18)                                                                0.0227   19 (37)   1 (5)     0.0042
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Questionnaire+PEF results suggest that further diagnostic evaluation is warranted (yes/no).

COPD, FEV~1~ 60%--80% predicted, and no history of exacerbations \>12 months.

Sensitivity=39.7%; specificity=93.1%; error=31.3% for milder patients versus no COPD.

Sensitivity=71.2%; specificity=83.9%; error=21.9% for milder patients versus no COPD.

Chi-square (*χ*^2^) or Fisher's exact (cell n\<5).

**Abbreviations:** CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; PEF, peak expiratory flow.
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![The CAPTURE™ (COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk) questionnaire.\
**Notes:** Scoring: No =0; Yes =1; Item 5: 0, 1, 2. Scores are summed. © Cornell University, University of Kentucky Research Foundation, and Evidera, Inc. All rights reserved.](copd-13-1901Fig1){#f1-copd-13-1901}

![ROC and AUC by group.\
**Notes:** (**A**) milder^a^ (n=73) versus No COPD^b^ (n=87); (**B**) severe, high-risk COPD^c^ (n=186) versus no COPD^d^ (n=87); (**C**) all COPD^e^ (n=259) versus no COPD^f^ (n=87). ^a^COPD, FEV~1~ 60%--80% predicted and no history of exacerbations \>12 months. ^b^No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70. ^c^FEV~1~ \<60% or exacerbation risk. ^d^No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.^1\ e^Medical diagnosis and treatment for COPD; FEV~1~/FVC \<0.70. ^f^No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.\
**Abbreviations:** AUC, area under the curve; CAPTURE™, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; ROC, receiver operating characteristics.](copd-13-1901Fig2){#f2-copd-13-1901}

###### 

Demographic characteristics by group[a](#tfn1-copd-13-1901){ref-type="table-fn"}

  Characteristic                                                         n=160        *p*-value     
  ---------------------------------------------------------------------- ------------ ------------- ----------------------------------------------------
  Age (years)                                                                                       
   Mean (SD)                                                             65.2 (9.1)   58.1 (10.5)   \<0.0001
   Range                                                                 49--85       40--88        
  Sex, n (%) male                                                        40 (55)      26 (30)       0.0014
  Ethnic background, n (%)                                                                          
   Not Hispanic or Latino                                                68 (99)      84 (99)       1.000
  Racial background, n (%)[d](#tfn4-copd-13-1901){ref-type="table-fn"}                              
   White                                                                 66 (90)      73 (84)       0.2250[a](#tfn1-copd-13-1901){ref-type="table-fn"}
   Non-white                                                             7 (10)       14 (16)       
  Employment, n (%)                                                                                 
  Employed (full- or part-time)                                          15 (21)      55 (63)       \<0.0001
   Not employed                                                          58 (79)      32 (37)       
   Retired                                                               37 (51)      22 (25)       
   Disabled                                                              18 (25)      3 (3)         
   Others[e](#tfn5-copd-13-1901){ref-type="table-fn"}                    3 (4)        7 (8)         
  Education status, n (%)                                                                           0.0006
   High school or less                                                   36 (49)      18 (21)       
   Some college, vocational training                                     14 (19)      22 (25)       
   College degree or more                                                23 (32)      47 (54)       

**Notes:**

English-speaking with informed consent and spirometry.

COPD, FEV~1~ 60%--80% predicted, and no history of exacerbations \>12 months.

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.

Subject self-identified; American Indian or Alaskan Native (1,1), Asian (0,1), Black or African American (11, 5), and others (2,0).

Others: homemaker, unemployed, and not specified.

**Abbreviation:** FEV~1~, forced expiratory volume in 1 second.

###### 

Clinical characteristics by group[a](#tfn7-copd-13-1901){ref-type="table-fn"}

  Characteristic                             n=160            *p*-value        
  ------------------------------------------ ---------------- ---------------- ----------
  Smoking history, n (%)                                                       \<0.0001
   Never or \<100 cigarettes                 2 (3)            51 (59)          
   Former                                    48 (66)          28 (32)          
   Current                                   23 (32)          8 (9)            
  Spirometry                                                                   
   FEV~1~, median                            2.0              2.6              \<0.0001
   Mean (SD)                                 2.1 (0.6)        2.6 (0.7)        
   FEV~1~% predicted                         70.0             93.0             \<0.0001
   Mean (SD)                                 74.0 (12.4)      89.7 (14.6)      
   FEV~1~/FVC, mean (SD)                     0.6 (0.1)        0.8 (0.1)        \<0.0001
  Peak flow (PEF)                            316.1 (102.86)   403.5 (109.00)   \<0.0001
  mMRC dyspnea scale (0--4 scale)                                              
   Median                                    2                1                \<0.0001
   Mode (n, %)                               1 (34; 46)       0 (71; 82)       
   mMRC \>2                                  20 (28)          5 (6)            
  CAT™ (0--40 scale)                                                           
   Median                                    15.0             4.0              \<0.0001
   Mean (SD)                                 15.6 (8.0)       5.5 (5.4)        
   CAT \>10, n (%)                           57 (78)          13 (15)          \<0.0001
  mMRC \>2 or CAT \>10, n (%)                57 (78)          15 (17)          \<0.0001
  mMRC \>2 and CAT \>10, n (%)               20 (28)          3 (3)            \<0.0001
  Comorbid conditions (any), n (%) yes       73 (100)         76 (87)          0.0010
  Self-report activity on most days, n (%)                                     0.0524
   Sit, lie down, walk around home           38 (52)          32 (37)          
   Very active or exercise                   35 (48)          55 (63)          

**Notes:**

English-speaking subjects with informed consent and spirometry.

COPD, FEV~1~ 60%--80% predicted, and no history of exacerbations \>12 months.

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥0.70.

**Abbreviations:** CAT, COPD Assessment Test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council dyspnea scale; PEF, peak expiratory flow.

###### 

Performance properties for questionnaire, PEF, and CAPTURE for differentiating COPD from no COPD

  A                                             
  ----------------- ------ ------ ------ ------ ------
  Sensitivity (%)   83.6   38.4   83.6   39.7   71.2
  Specificity (%)   67.8   90.8   66.7   93.1   83.9
  Error (%)         25.0   33.1   25.6   31.3   21.9

  B                               
  ----------------- ------ ------ ------
  Sensitivity (%)   95.7   88.0   89.7
  Specificity (%)   67.8   90.8   93.1
  Error (%)         13.2   11.1   9.2

  C                                             
  ----------------- ------ ------ ------ ------ ------
  Sensitivity (%)   92.3   73.9   94.2   75.5   88.0
  Specificity (%)   67.8   90.8   66.7   93.1   83.9
  Error (%)         13.9   21.8   12.8   20.1   13.0

**Notes:**

(**A**) COPD, FEV~1~ 60--80% predicted and no history of exacerbations \>12 months;

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥ 0.70;

Peak expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females;

CAPTURE = Questionnaire + PEF.

(**B**) COPD, FEV~1~ \< 60% predicted or exacerbation risk;

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥ 0.70;

Peak expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females;

CAPTURE = Questionnaire + PEF.

(**C**) Medical diagnosis and treatment for COPD; FEV~1~/FVC \< 0.70;

No known diagnosis or treatment for COPD and FEV~1~/FVC ≥ 0.70;

Peak expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females (n=344);

CAPTURE = Questionnaire + PEF.

**Abbreviations:** CAPTURE, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.
